Fate Of AstraZeneca's Iressa To Be Discussed By Advisory Cmte. March 4
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will seek input from its Oncologic Drugs Advisory Committee on whether Iressa's accelerated approval should be withdrawn after the non-small cell lung cancer agent failed to show a survival benefit in a confirmatory trial.